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Abstract
It is important to identify effective contraceptive drugs that cause minimal disruption to physiological processes.
Phosphodiesterase 3 (PDE3) inhibitors suppress meiosis in oocytes by decreasing the level of cAMP and blocking the
extrusion of the first polar body. In this study, we tested the PDE3 inhibitor, cilostazol, as a potential contraceptive agent.
The effects of cilostazol treatment in vitro and in vivo on the suppression of oocyte maturation in a mouse model were
investigated. The results indicated that treatment with increasing concentrations of cilostazol led to a dose-dependent
arrest in meiosis progression. The effective in vitro concentration was 1 mM and was 300 mg/kg in vivo. The effect of
cilostazol was reversible. After removal of the drug, meiosis resumed and mouse oocytes matured in vitro, and showed
normal chromosome alignment and spindle organization. After fertilization using an ICSI method, the oocytes showed
normal morphology, fertilization rate, embryo cleavage, blastocyst formation, and number of viable pups when compared
with controls. The offspring showed similar body weight and fertility. In vivo, the mice became infertile if the drug was
injected sequentially, and became pregnant following discontinuation of cilostazol. More importantly, no side effects of
cilostazol were observed in treated female mice as demonstrated by blood pressure and heart rate monitoring. It is
concluded that cilostazol, a drug routinely used for intermittent claudication, can effectively inhibit oocyte maturation in
vitro and in vivo, does not affect the developmental potential of oocytes following drug removal and has few side effects in
female mice treated with this drug. These findings suggest that cilostazol may be a potential new contraceptive agent that
may facilitate an efficacy and safety study of this drug.
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Introduction
The current steroid-based contraceptive pills are reversible and
effective. They also decrease the incidence of ovarian and
endometrial tumors [1]. However, thrombogenic and other side
effects in some women taking these steroid-based contraceptive
pills have been reported [2], and the effects of these drugs on
future generations are still unclear. The ideal contraceptive should
act on the ovary to block oocyte maturation during the process of
ovulation without disrupting the menstrual cycle.
In mammals, oocyte meiosis is arrested at the germinal vesicle
(GV) phase in growing follicles. Before ovulation, the LH surge
induces granulosa cells to secrete cyclic adenosine monophosphate
(cAMP) which leads to follicle rupture [3,4]. However, in oocytes, a
decrease in intra-oocyte cAMP levels is required for the resumption
of meiosis. Earlier studies demonstrated that spontaneous matura-
tion of mouse oocytes in vitro when released from their follicles can
be reversibly blocked by the addition of a derivative of cAMP or a
phosphodiesterase (PDE) inhibitor and the PDE3 was localized in
oocytes [5]. Treatment with a PDE3 inhibitor did not affect follicle
rupture and reproductive cyclicity in mice but elevated cAMP levels
in oocytes and suppressed GV breakdown, leading to a new
contraceptive approach [6]. Thus, by increasing the level of cAMP
with pharmacological or molecular approaches, one can inhibit
meiosis in oocytes and induce contraception.
To date, ORG9935 is one of the widest studied PDE3 inhibitors
as a potential contraceptive. Oocytes retrieved from immature
follicles were arrested in prophase I with a high efficiency for up to
72 h when cultured with ORG9935 (10 mM) [7]. A series of
experiments on macaques found that ORG9935 selectively
blocked the spontaneous resumption of meiosis in macaque
oocytes in vitro and inhibited oocyte maturation in gonadotropin-
stimulated and in natural ovarian cycles in rhesus macaques
without affecting follicle rupture [8–10]. The effective dosage of
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30649ORG9935 for oocyte meiotic arrest in rhesus macaques was also
determined [11]. It has been proposed that this PDE3 inhibitor
could be a potential oral contraceptive. However, treatment with
ORG9935 in rodents increased heart rate [6] and ORG9935 is
not a clinical medicine approved by the US Food and Drug
Administration (FDA). Therefore, it is still necessary to develop
other PDE3 inhibitors approved by FDA and study their potential
as contraceptives.
Figure 1. Developmental stages of mouse oocytes after treatment of COCs and DOs with cilostazol and ORG9935 at different
concentrations for 24 h. As the concentration increased, the percentage of oocytes showing meiotic arrest increased (P,0.05). (A) Cilostazol and
(B) ORG9935. Orange dot line represents COCs at GV stage, orange hyphen line represents COCs at GVBD stage, and orange straight line represents
COCs at MII stage. Blue DOs dot line represents COCs at GV stage, blue hyphen line represents DOs at GVBD stage, and blue straight line represents
DOs at MII stage.
doi:10.1371/journal.pone.0030649.g001
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hydro-2-(1H)-quinolinone, another PDE3 inhibitor, has been
shown to increase cellular levels of cAMP by inhibiting its
degradation, it also inhibits platelet aggregation [12], serving as an
arterial vasodilator. Importantly, it has been approved as a
therapeutic agent for intermittent claudication [13]. However, the
possible regulation of oocyte maturation in vitro and in vivo by
cilostazol has yet to be studied.
The aim of this study is to investigate the effects of cilostazol on
meiotic arrest and maturation of mouse oocytes in vitro as well as
the potential use of cilostazol as a contraceptive in vivo in mice. The
effects of prior exposure to cilostazol on chromosome alignment
and spindle organization in oocytes, development during preg-
nancy and full-term development of embryos after removal of
cilostazol were also studied. Furthermore, the physiology indexes
of mice treated with this drug and their offspring was investigated.
Results
Effects of different concentrations of cilostazol on the
maturation of mouse oocytes in vitro
To study the optimal concentration of cilostazol for the
inhibition of mouse oocyte maturation, different concentrations
of cilostazol were added to the IVM medium containing mouse
cumulus-oocyte complexes (COCS) and denuded oocytes (Dos). A
dose-dependent suppression of meiotic progression was observed
(Fig. 1A). With increased concentrations of cilostazol, the meiotic
arrest rate of GV oocytes was also increased, and meiotic arrest
was completely inhibited at 1 mmol/L. The effects of different
concentrations of ORG9935 on mouse oocytes were also
evaluated as a positive control and were consistent with those
found in cilostazol treatment (Fig. 1B).
Reversible effects of cilostazol on the developmental
competence of oocytes and embryonic development
Following removal of cilostazol, meiosis resumed within
20 hours which is normal in IVM. Some of the IVM oocytes
which recovered from meiotic arrest were tested for spindle
organization and chromosome alignment. The results showed that
there was no significant difference between IVM oocytes treated
with cilostazol and control IVM oocytes (P.0.05). More than 80%
of IVM oocytes in the treatment and control groups showed
normal spindle organization and chromosome alignment, and
spindle configuration was regarded as morphologically normal
when the meiotic spindle showed an oblong structure. Chromo-
some configuration was regarded as normal when chromosomes
were located exclusively on the equatorial plate (Table 1). The
representative morphology is shown in Fig. 2.
Some of the IVM oocytes were fertilized using the ICSI method
to assess the developmental potential of the oocytes treated with
cilostazol. Successful fertilization was assessed by the formation of
male and female pronuclear. Some fertilized embryos were
cultured in vitro to assess the preimplantation development
potential. The rates of fertilization and cleavage in vitro were
78.3% and 83.1%, respectively, which were not significantly
different from the control group (P.0.05). The rate of blastocyst
formation was also comparable between the two groups, showing
no significant difference (P.0.05) (Table 2). Other fertilized
embryos were transferred into female recipients to assess full-term
Figure 2. The distribution and organization of microtubules and spindles in IVM oocytes treated and not treated with cilostazol. (A)
Representative normal spindle and chromosome alignment in the treatment group. (B) Representative normal spindle and chromosome alignment in
the non-treatment group. Original magnification 6400.
doi:10.1371/journal.pone.0030649.g002
Table 1. A summary of a-tubulin expression and nuclear
location in IVM oocytes in cilostazol treatment and non-
treatment groups.
Group
No. of
oocytes
Normal
Metaphase
Abnormal
Metaphase
Treatment 22 16 (72.7)
a 6 (27.3)
a
Non-treatment 28 21 (75.0)
a 7 (25.0)
a
aValues with same superscripts in the same column are comparable (P.0.05).
doi:10.1371/journal.pone.0030649.t001
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significant difference between the treatment and control groups
(P.0.05) (Table 2).
Two key physiological indices of offspring were analyzed: body
weight and fertility. The results of body weight analysis indicated
that there was no significant difference between female and male
offspring in the treatment and control groups (P.0.05). However,,
the body weight of male offspring in the seven-week and sixteen-
week age in the treatment group was significant lower compared
with the control group (P,0.05) (Fig. 3A and B). The fertility
assessment demonstrated that there were no significant differences
between the treatment and control groups (P.0.05), irrespective
of when the female or male mice were mated. No significant
differences in litter size and sex ratio were observed between the
two groups (P.0.05) (Fig. 3C and D).
Effects of different concentrations of cilostazol on the
oocyte maturation, pregnancy and heart cardiovascular
parametes in female mice
Based on in vitro studies, we injected cilostazol into female mice
to evaluate its role in the suppression and inhibition of oocyte
maturation and pregnancy. Mice treated with ORG9935 acted as
positive controls. The results showed that cilostazol had a dose-
dependent effect on in vivo maturation of oocytes. With increased
concentrations of cilostazol, the rate of mature MII oocytes was
decreased, and meiotic arrest was completely inhibited at 300 mg/
kg, and approximately 14.5% of oocytes treated with ORG9935
were not inhibited and achieved maturation, the effective
concentration of ORG9935 was 500 mg/kg (Fig. 4).
Female mice treated with the cilostazol were mated with male
mice. The results suggested that the mice injected consecutively
with cilostazol did not become pregnant although vaginal plugs
were found in the morning. However, mice injected with the same
volume of 0.9% physiological saline solution became pregnant and
produced offspring after plugs were observed. Following the
removal the cilostazol, fertility was restored in female mice within
a short time, they became pregnant and produced offspring, and
the litter size in treated mice was not significantly different from
that in non-treated mice (Fig. 5A and B).
To identify possible side effects of cilostazol in female mice, the
blood pressure and heart rate of female mice injected with
cilostazol were monitored. The results showed that heart rate was
not significantly different between the treatment and control
groups (P.0.05), and the results for systolic and diastolic blood
pressure (SBP and DBP) were similar (Table 3).
Discussion
In the present study, we first described the role of cilostazol, a
PDE3 inhibitor, on the suppression of mouse oocyte maturation in
vitro and in vivo, and demonstrated the effects of cilostazol on IVM
oocytes and the resulting embryos and offspring. PDE are enzymes
that can degrade and inactivate cAMP [14]. PDE3 is a member of
the PDE family, and is found in the oocytes of mice [15], cattle
[16], and humans [7]. Inhibition of PDE3 can increase the level of
cAMP, resulting in oocyte GVBD blockage [16–25]. PDE3A
regulates the resumption of meiosis up to 3 h prior to GVBD and
transiently affects meiotic progression [16,26]. PDE3A-deficient
mice with oocytes containing increased cAMP levels failed to
undergo spontaneous maturation; however, the animals were
viable and showed no other abnormalities [26]. Adult cycling rats
treated with a PDE3 inhibitor completely prevented viable
pregnancy, but maintained estrous cycles (and ovarian hormone
production) [6].
Our study showed that cilostazol effectively inhibited mouse
oocyte maturation in vitro and in vivo. These results may provide a
potential new approach for future contraceptives. The effective
concentration of cilostazol was identified by in vitro and in vivo
experiments using a mouse model, and reversibility tests indicated
that the developmental competence of the oocytes was not
impaired following removal of the drugs and allowed ovulation
and oocyte maturation. In the in vitro experiments, ORG9935
suppressed meiosis at the concentration of 1 mmol/L, consistent
with the findings of a previous study [16].
It is a concern for users as to whether the developmental
competence of oocytes would be impaired by this drug. Using the
mouse model, the dynamics of the spindle and chromosome
apparatus were identified, and the results suggested that there was
no significant difference between the treatment and control
groups. Moreover, the resulting fertilized embryos had similar
development potential in the preimplantation and full-term
development stages as those in the control group. In our study,
treatment with cilostazol did not affect the development potential
of treated oocytes after drug removal, Similarly, mouse follicles
treated with ORG9935 in IVM medium did not affect somatic cell
function, differentiation, or oocyte growth and maturation [27].
In the present study, we found that cilostazol was safer than
ORG9935. Wiersma et al. indicated that ORG9935 could induce
an increase in heart rate in rodents. However, in our study, the
heart rate in female mice treated with cilostazol was normal and
not significantly different to that in the control group. The mating
experiment was used to assess the fertility of mice treated with this
drug and to determine the safety of this drug. The mice treated
with cilostazol were infertile, and immediately became pregnant
after its removal. The litter size and sex ratio of the offspring from
the treated oocytes and normal IVM oocytes were similar. All
these data demonstrate that cilostazol is effective and safer than
the PDE3 previously reported.
Furthermore, cilostazol has been approved in the U.S. for the
treatment of symptoms of intermittent claudication (IC) since 1999
and for related indications since 1988 in Japan and other Asian
countries [28]. Other PDE3 inhibitors such as milrinone have
Table 2. Effects of cilostazol treatment in vitro and in vivo on the early and full-term development of ICSI embryos.
Group
No. of
oocytes No. fertilized (%) Development stage (%)
No. of transferred
embryos
No. of full-term
fetuses (%)
2-cell 8-cell Blastocyst
Treatment in vitro 83 65 (78.3)
a 54 (83.1)
a 33 (64.1)
a 23 (42.6)
a 30 14 (46.7)
a
Control in vitro 77 62 (80.5)
a 50 (80.6)
a 30 (60.0)
a 18 (36.0)
a 30 16 (53.3)
a
aValues with same superscripts in the same column are comparable (P.0.05).
doi:10.1371/journal.pone.0030649.t002
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however, no such side effects have been described for cilostazol
[29]. Cilostazol has also been confirmed to be beneficial in
different circulatory symptoms [12,30,31]. If the correct dosage is
identified to minimize side effects, this agent may be a safe
contraceptive.
In conclusion, we found that cilostazol blocked maturation of
mouse oocytes both in vitro and in vivo. The reversibility of this drug
was determined based on the resumption of oocyte meiosis and
blastocyst formation as well as full-term development of fertilized
embryos. The effectiveness of cilostazol was proved by the mating
experiment, which indicated the potential of cilostazol as a
contraceptive drug. These findings may not only provide a new
choice of contraceptive, but may promote and facilitate future
studies on the mechanisms of action of contraceptive drugs on
oocyte and embryo development.
Materials and Methods
All chemicals were from Sigma Chemical Co. (Sigma, USA)
unless otherwise indicated. ORG9935 and cilostazol were stored
at 10 mM in dimethyl sulfoxide (DMSO) at 220uC. In
preliminary experiments, the highest concentration of the DMSO
carrier (0.1% v/v) was tested for 24 h in IVM medium and no
effect on maturation was observed.
Experimental design
A schematic diagram of the study is shown in Figure S1.
Experiment 1 was primarily designed to determine the lowest
effective dose of cilostazol that arrested oocytes in vitro at the GV-
stage with full reversibility of the inhibitory effect. Different
concentrations were tested: 0 (control), 0.001, 0.01, 0.1, 0.3, 1
and 10 mM. After 24 h of incubation with cilostazol, groups of
cumulus-oocyte complexes (COCs) were denuded, and were
classified by light microscopy as GV, GV breakdown (GVBD) or
polar body extrusion (PB). Experiment 2 determined the spindle
organization and chromosome alignment of IVM oocytes following
removal of cilostazol, and the developmental potential of the
resulting embryos fertilized by the ICSI method in the early stage of
development and at full-term. Body weight and reproductive ability
in offspring were also analyzed. Experiment 3 was an in vivo
experiment which assessed whether cilostazol affected the fertility of
mice, and the side effects induced by this drug.
Mice and collection of oocytes
ICR inbred mice (CD-1, Animal Center of Medical College of
Peking University), at 8–10 weeks of age were housed and bred in
the Animal Center of Medical College of Peking University
according to national legislation for animal care. Mice at the
proestrous stage were injected intraperitoneally with 10 IU
pregnant mare serum gonadotropin (PMSG) and sacrificed 48 h
later by cervical dislocation in order to obtain COCs and denuded
oocytes (DOs) from small antral follicles. The ovaries were
dissected and collected in Leibovitz-15 medium, supplemented
with 10% fetal calf serum (FBS, GIBCO), 100 mg/ml streptomy-
cin, and 100 IU/ml penicillin. To prevent spontaneous resump-
tion of meiosis, cilostazol or ORG9935 was added to this medium
at the same final concentration as used in the IVM medium.
Figure 3. Measurements of body weight and fertility in offspring from oocytes treated and not treated with cilostazol. (A) body
weight of female mice, (B) body weight of male mice, (C) fertility of female mice, (D) Fertility of male mice. The value of the litter size is not a
percentage, but numerical data. In image (A) and (B), Black hyphen line with diamond represents mice conceived from female mice treated with
cilostazol before, and black straight line with square represents mice conceived from female mice without cilostazol treatment. In image (C) and (D),
Black solid rectangle represents cilostazol treatment group, and black hollow rectangle represents control group without cilostazol treatment.
doi:10.1371/journal.pone.0030649.g003
Figure 4. Effects of in vivo treatment with different concentrations of cilostazol and ORG9935 on the GVBD ratio of oocytes in mice.
Orange straight line represents cilostazole treatment group, and blue straight line represents ORG9935 treatment group.
doi:10.1371/journal.pone.0030649.g004
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antral follicles with fine needles. Only DOs with a GV and COCs
consisting of an oocyte surrounded by a compact cumulus-cell
mass were selected for the experiments.
For in vivo experiments, oocytes were obtained by priming mice
with 10 IU/ml PMSG followed at 48 h by an injection of 10 IU
human chorionic gonadotropin (hCG). Two hours before injecting
hCG, mice were given ORG9935 or cilostazol by feeding at
concentrations of 30 mg/kg, 60 mg/kg, 150 mg/kg, 300 mg/kg,
and 500 mg/kg. After sacrificing the mice, COCs were obtained
from the oviduct. To assess oocyte development, we used 80 IU/
ml hyaluronidase to remove the cumulus cells surrounding the
oocytes.
In vitro maturation of oocytes
Immediately after aspiration, the oocytes were washed and
placed into 15 ml droplets containing different concentrations of
the drugs overlaid with oil. The IVM medium (Invitrogen,
Sweden) was prepared the day before and supplemented with
10 U/L FSH and LH. The drugs were added to the IVM medium
before oocyte retrieval. All cultures were carried out at 37uCi na
humidified atmosphere in an incubator gassed with 5% CO2 in
air. At 24 h of culture, the stages of oocyte development were
recorded and oocytes with PB I were removed from culture.
Oocytes were denuded mechanically by repeated pipetting and
were assessed for maturation by scoring for GV, GVBD and PB1.
Figure 5. Effects of cilostazol administration on the fertility of female mice. (A) treated with cilostazol, (B) treatment with cilostazol
stopped. The value of the litter size is not a percentage, but numerical data. In image (A), Black solid rectangle represents cilostazol treatment group,
and black hollow rectangle represents control group without cilostazol treatment. In image (B), Black solid rectangle represents cilostazol treatment
group, but stopped treatment at present, and black hollow rectangle represents control group without cilostazol treatment.
doi:10.1371/journal.pone.0030649.g005
Table 3. Comparison of heart rate and blood pressure in
mice before and after cilostazol administration (Mean 6
S.E.M).
Groups Blood pressure Heart rate
SBP (mmHg) DBP (mmHg)
Before treatment 105.47564.134
a 67.78864.058
a 367.315631.459
a
After treatment 108.10064.375
a 70.07564.200
a 395.949633.750
a
aValues with same superscripts in the same column are comparable (P.0.05).
doi:10.1371/journal.pone.0030649.t003
Cilostazol Inhibits Oocyte Maturation
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30649Immunofluorescence staining and confocal analysis
Mature (IVM) oocytes were fixed with 4% paraformaldehyde in
phosphate-buffered saline (PBS) in vitro for 30 min at room
temperature. They were then permeabilized in incubation buffer
(1% Triton X-100 in PBS) for 15 min at 37uC in an incubator.
This was followed by blocking in 1% BSA for 1 h and overnight
incubation at 4uC with rabbit anti-a-tubulin antibody (1:100) for
spindle staining. After three washes in PBS with 0.1% Tween-20
and 0.1% Triton X-100 for 5 min, the oocytes were incubated
with FITC-conjugated goat anti-rabbit IgG (1:100, Santa Cruz
biotechnology, Inc, US) at 37uC for 1 h. The oocytes in the
control group were only incubated with the FITC-conjugated
secondary antibody. The oocytes were then incubated with PI at
room temperature for 15 min. The oocytes were observed using a
laser scanning confocal microscope (LSCM; Biorad Radiance
2000 mounted on a Nikon inverted microscope; Tokyo, Japan) to
analyze spindle size, shape and chromosome alignment.
Intracytoplasmic sperm injection, embryo culture and
embryo transfer
After removal of the drugs at 1 mmol/L, the oocytes were
cultured in IVM medium for 20 h and MII oocytes were used for
ICSI. Sperm collected from the cauda epididymis of adult ICR
mice was washed twice with injection buffer (75 m mol/L KCl
and 20 m mol/L HEPES, pH 7.0), then treated with buffer
containing 12% polyvinylpyrrolidone. Active sperm was delivered
into the oocyte cytoplasm using a Piezo micropipette-driving unit
as described [32]. A slight piezo-electric pulse was applied to
puncture the oocyte plasma membrane following penetration of
the zona pellucida. Mouse sperm heads were separated from tails
by applying a few piezo-pulses at the mid-piece of the sperm,
immediately prior to injection into the oocyte. Activation was
assessed by the number of zygotes with extrusion of the second PB
and two pronuclei at 6 h post-ICSI, and cleavage to the 2-cell
stage after 24 h. In vitro development of embryos was assessed by
monitoring progression to the blastocyst stage on day 4.
After ICSI manipulation, the embryos showing two-pronuclei
(2PN) were transferred to the oviduct of pseudopregnant CD-1
females and the pregnant mice delivered naturally on day 19.5.
The offspring were maintained under controlled temperature and
lighting conditions, and given food and water ad libitum. Postnatal
development of mice was evaluated according to a panel of
physiological indices, including body weight and reproductive
ability.
Body weight
The offspring were weighed weekly before 10 weeks and once
every two weeks after 10 weeks.
Measurement of blood pressure and heart rate
Individual mice were placed in a cage on the warmplate at 37uC
for half an hour. Then systolic blood pressure (SBP) and heart rate
(HR) were measured by the tail-cuff method with a Softron BP
system (Softron BP-98A, Tokyo, Japan). The measured mice were
put back into the cage to rest, then injected with 300 mg/kg
cilostazol, and allowed to calm down in the cage on the warmplate
at 37uC for 2 h. SBP and heart rate (HR) were then measured by
the tail-cuff method with a Softron BP system.
Fertility studies
Female mice receiving cilostazol were mated, and the vaginal
plugs were checked every morning during the following two weeks.
Female mice with plugs were separated and fed individually in
cages.
In the offspring, the female and male mice were mated, and the
pregnant mice were separated and fed individually in cages. The
litter size and the sex ratio were recorded.
Statistical analysis
Experiments were performed at least three times and P#0.05
was considered statistically significant. The values are given as
means 6S.E.M. For the data on oocyte maturation, n refers to the
number of oocytes. Maturation frequencies were subjected to
arcsine transformation and analyzed by ANOVA followed by
Duncan’s multiple range tests.
Supporting Information
Figure S1 A schematic diagram of the study.
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